IDIX研究所は大きな投資と 強い収益率と 546ドルの目標価格を見ています 
IDIX Laboratories sees big investments, strong earnings beat, and a $546 target price.
獣医や水検査市場向け製品を製造するIDIX Laboratoriesは,モルガン・ロセル・ウェルツ・マネジメントやBNPパリバなどの企業から大きな投資を受け,スパイア・ウェルツ・マネジメントは保有量を削減した. IDIX Laboratories, a company that produces products for veterinary and water testing markets, saw significant investment from firms like MorganRosel Wealth Management and BNP Paribas, while Spire Wealth Management reduced its holdings. "中等買い"の評価と目標価格546.00ドルの株は,予想の2.93ドルと比較してEPS2.96ドルで,強い利益率を報告した. The stock, which has a "Moderate Buy" rating and a target price of $546.00, reported a strong earnings beat, with EPS of $2.96 compared to the expected $2.93. 会社の市場資本化は4.3.13億円です. The company's market capitalization is $43.13 billion.
